Cingulate receives first U.S. patent for ADHD drug candidate CTx-1301
Go back to Cingulate receives first U.S. patent for ADHD drug candidate CTx-1301| (NASDAQ: CING) | Delayed: 5.09 +0.10 (2.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.99 | 52 Week High | $ | |||
| Open | $4.92 | 52 Week Low | $ | |||
| Day High | $5.13 | P/E | N/A | |||
| Day Low | $4.71 | EPS | $ | |||
| Volume | 207,426 | |||||
| (NASDAQ: CINGW) | Delayed: 0.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.01 | 52 Week High | $ | |||
| Open | $0.01 | 52 Week Low | $ | |||
| Day High | $0.01 | P/E | N/A | |||
| Day Low | $0.01 | EPS | $ | |||
| Volume | 9,699 | |||||
